ESR1 and cancer: This active mRNA/miRNA signature was also identified in 40% of matched cancer‐adjacent breast tissues (n = 142) from the TCGA breast cohort, with this subtype associated with worse poor 10‐year survival in estrogen receptor‐positive patients [72].